retatrutide phase 2 results 2024 2025 press release clinical trial Lilly, with new data, to seek FDA approval of obesity drug June 8, 2026: Reckless physicians – Lilly's triple agonist delivers up

N i,j , the sample size in study i with time point j

Given the rising burden of obesity, this chronic disease is going to be managed by specialists of many stripes beyond primary care and endocrinology, he said

The available evidence indicates quite convincingly that SSRI use may play a causal role in upper gastrointestinal bleeding and that these drugs may act synergistically with other bleeding risk-increasing medications such as NSAIDs or low-dose aspirinPatients should be informed about the likelihood of possible upper gastrointestinal bleeding and high-risk patients should be followed closely. Psychiatric Drugs and ALS A research team at the Karolinska Institute in Sweden announced a worrisome drug complication ( JAMA Network Open , June 4, 2025)

No food 2-3 hours before bed

2540% lean mass loss (includes muscle + water + glycogen) lean mass loss is real and measurable

Sikiric, P., Seiwerth, S., Rucman, R., Drmic, D., Stupnisek, M., Kokot, A.,